HOW FOUR KEY EVENTS OF 2022 WILL IMPACT THE PHARMACEUTICAL ENVIRONMENT IN 2023
February 2023Don Sancton (with insights from Fred Horne) | Provincial Reimbursement Advisor
PROFILES IN REIMBURSEMENT – CONTRIBUTIONS MADE BY THE CANADIAN INSTITUTE FOR HEALTH INFORMATION
May 2023Gerry Jeffcott | Provincial Reimbursement Advisor
HOW WILL NEW DRUGS FOR OBESITY AND ALZHEIMER’S DISEASE BE RECEIVED BY CANADIAN PUBLIC PAYERS?
May 2023Don Sancton | Provincial Reimbursement Advisor
PHARMAFOCUS 2026 UPDATE
November 2022Gerry Jeffcott, Bill Dempster, Don Sancton, Michel Parent, Stephanie Levee | IQVIA
Profiles in reimbursement – The important and ever-evolving role of CADTH
May 2022Gerry Jeffcott and Don Sancton | Provincial Reimbursement Advisor
PHARMAFOCUS 2026
June 2022Gerry Jeffcott, Bill Dempster, Don Sancton, Michel Parent, Stephanie Levee | IQVIA
Profiles in reimbursement – The important and ever-evolving role of the pCPA
November 2022Gerry Jeffcott | Provincial Reimbursement Advisor
The road to national pharmacare in Canada: Where will the federal NDP-Liberal agreement take us?
August 2022Don Sancton | Provincial Reimbursement Advisor
Oh national rare disease treatment strategy, wherefore art thou?
August 2022Gerry Jeffcott | Provincial Reimbursement Advisor
Is Canada spending what it should on medications?
February 2022Gerry Jeffcott | Provincial Reimbursement Advisor